June 20 – Nouscom: developing the next generation immunotherapeutics for selective tumor killing

This Life Science event will have Dr. Marina Udier, CEO of Nouscom, talking about the story of the company and sharing insights and learnings along the way.

Nouscom is a Basel-based clinical-stage oncology company launched in 2015 and backed by an impressive roster of international life science investors: 5AM, Abingworth, Life Sciences Partners (LSP) and Versant Ventures. Nouscom raised 54 million Euro of venture capital to date in two financing rounds.

The company develops next generation cancer vaccines based on its proprietary Exovax platform, which harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Its lead program NOUS-209 is being developed as a therapeutic vaccine for cancers characterized by Microsatellite Instability. NOUS-209 is the first neoantigen off-the-shelf cancer vaccine tested in the clinic.

In 2017, Nouscom announced very compelling preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics’ NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials, demonstrating complete response in 100% of treated animals.

Learn more about their rapidly expanding portfolio, their plans for the future and their approach to developing personalized cancer vaccines.

When: 20.06.2019, 19:00 – 20:00
Where: Halle 7, Dornacherstrasse 192, Basel



Door opening




Dr. Marina Udier, CEO Nouscom    




Networking Apéro

Participation to the event is free of charge; however, your registration by 19th June 2019 is kindly required.

About the speaker

Marina Udier now CEO, has been the Chief Operating Officer of Nouscom AG since 2016,  where she has been responsible for all aspects of company’s business development, business operations and finance activities. Marina joined Nouscom as an Operating Principal from Versant Ventures. During her tenure with the Versant investment team, she identified new investment opportunities in Europe and worked with portfolio companies in Europe and US.

Prior to Versant, Marina was in various senior development and commercial roles at Novartis Pharma. As the Global Commercial Head, Near Patient Testing Unit, she developed global commercial strategy and launch plans for a point of care diagnostics platform. Marina led development and subsequent registration of a Companion Diagnostics (In Vitro Diagnostics) for RYDAPT™ (midostaurin), the first approved AML drug in over 3 decades. She managed the Global commercial Neurodegeneration portfolio for Novartis driving her Brands to a blockbuster status.
Marina spent 5 years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies, specializing in areas of marketing and strategy. Marina received her PhD in Chemistry from Yale University. She authored several peer reviewed publications in the area of HIV/AIDS research.